MedPath

Adebrelimab

Generic Name
Adebrelimab
Drug Type
Biotech
CAS Number
2247114-85-6
Unique Ingredient Identifier
1XBY50W1OX
Background

Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).

Indication

用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。

Clinical Trials
Related News

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

Phase 2
Recruiting
Conditions
Breast Cancer
Metastatic Cancer
Interventions
Drug: SERD
Drug: AI
First Posted Date
2022-01-25
Last Posted Date
2024-02-08
Lead Sponsor
Fudan University
Target Recruit Count
338
Registration Number
NCT05205200
Locations
🇨🇳

Fudan University Shanghai cancer center, Shanghai, China

Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors

Phase 1
Conditions
Tumor
Interventions
First Posted Date
2021-07-28
Last Posted Date
2021-07-28
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
15
Registration Number
NCT04979390

A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer

Phase 2
Conditions
Limited-stage Small Cell Lung Cancer, LS-SCLC
Interventions
First Posted Date
2020-11-30
Last Posted Date
2020-11-30
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
60
Registration Number
NCT04647357

SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC

Phase 2
Active, not recruiting
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Radiation: Radiation therapy
First Posted Date
2020-09-24
Last Posted Date
2024-07-03
Lead Sponsor
Shandong Cancer Hospital and Institute
Target Recruit Count
67
Registration Number
NCT04562337
Locations
🇨🇳

Shandong Cancer Hospital and Institute, Jinan, Shandong, China

Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer

Phase 3
Recruiting
Conditions
Colorectal Cancer
Vitamin C
GLUT3
Interventions
Drug: FOLFOX Protocol
First Posted Date
2020-08-18
Last Posted Date
2024-10-24
Lead Sponsor
Fudan University
Target Recruit Count
400
Registration Number
NCT04516681
Locations
🇨🇳

Fudan university shanghai cancer center, Shanhai, Shanghai, China

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

Phase 2
Recruiting
Conditions
Breast Cancer
Interventions
Drug: Cisplatin/Carboplatin
First Posted Date
2020-03-11
Last Posted Date
2024-07-18
Lead Sponsor
Fudan University
Target Recruit Count
35
Registration Number
NCT04303988
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Phase 1
Completed
Conditions
Advanced Malignancies
Interventions
First Posted Date
2019-06-24
Last Posted Date
2023-09-28
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
14
Registration Number
NCT03995472
Locations
🇦🇺

John Flynn Private Hospital, Tugun, Queensland, Australia

🇦🇺

Sydney Southwest Private Hospital, Liverpool, New South Wales, Australia

🇦🇺

Scientia Clinical Research, Randwick, New South Wales, Australia

and more 2 locations

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

Phase 2
Conditions
Advanced Esophageal Squamous Cell Cancer
Interventions
First Posted Date
2018-11-06
Last Posted Date
2018-11-06
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
30
Registration Number
NCT03732508
Locations
🇨🇳

Cancer Institute and Hospital,Chinese Academy of Medical Science, Beijing, Beijing, China

Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Phase 3
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Drug: Placebo
First Posted Date
2018-10-18
Last Posted Date
2022-04-18
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
462
Registration Number
NCT03711305
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

Jilin Cancer Hospital, Jilin, Changchun, China

Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors

Phase 1
Conditions
Tumor
Interventions
First Posted Date
2018-03-22
Last Posted Date
2018-03-22
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
134
Registration Number
NCT03474289
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy